Management

Circle33 has acquired all the patents, technology and assets of Avaxia Biologics for the development of orally administered, gut-targeted antibody therapeutics

Compelling market opportunity in adult and pediatric IBD estimated at approximately $9B worldwide with several additional applications

Circle33 is currently entertaining business arrangements to sell or license its technology for commercialization of these assets

To know more please contact us through email info@circle33llc.com